Piramal Pharma Limited has informed the Exchange about Completion of Acquisition

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

PPLPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.3%Reaction day

₹191.99

prior close

₹190.00

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.1%+0.2% vs market

Pharmaceuticals peers, median of 151sector+0.0%+0.3% vs sector

On the reaction day the stock moved 0.2 pts more than Nifty Smallcap 250 and 0.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.4

10m

+1.1

15m

+1.1

30m

+1.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.3+0.1+0.2+0.0+0.3

Next day

+0.4-0.1+0.5-0.2+0.6

+0.3-0.0+0.3-0.6+0.9

-1.2-1.9+0.6-1.6+0.4

-3.0-3.0-0.1-2.7-0.4

-4.6-3.3-1.3-2.3-2.3

-2.7-1.3-1.4-1.4-1.4

15d

+4.6+0.5+4.1-0.4+5.0

+5.7+1.6+4.0+0.1+5.6

+2.3+1.3+1.0-2.6+5.0

-2.3-2.0-0.3-6.6+4.2

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 151Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Piramal Pharma Limited announced that its step-down wholly owned subsidiary, Piramal Healthcare Inc., has completed the subscription of 1,903 optionally convertible redeemable preference shares in another step-down wholly owned subsidiary, PPL Pharma Inc. The total investment is valued at USD 190.3 million (approximately ₹1,626.49 crore), with each share having a face value of USD 100,000. This is a follow-up to the company's earlier intimation dated April 23, 2025. Since both entities involved are wholly owned subsidiaries of Piramal Pharma, this represents an internal capital infusion/restructuring within the group rather than a third-party deal.

Likely market impact

This is an internal group-level capital arrangement and is not expected to have a direct material impact on minority shareholders or the stock price. It signals continued internal financial restructuring and capital deployment within the Piramal Pharma group.